eligibility_summary
Eligible: adults (≥18) with multiple myeloma, measurable disease (IMWG), ECOG ≤2, triple-class refractory to a PI, IMiD, and anti‑CD38, and received ≥1 G‑BA standard‑of‑care treatment after TCR. Exclude: acute plasma cell leukemia, amyloidosis, smoldering MM, recent SCT (<12 wks) or active GVHD, other active malignancy within 3 yrs (except basal/squamous skin or in situ), investigational drug <30 days, or first post‑TCR therapy not G‑BA SoC.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study design: Retrospective comparative-effectiveness analysis in triple-class–refractory multiple myeloma comparing elranatamab (PF-06863135) versus real-world standard of care (SOC). Drug/intervention: Elranatamab (Elrexfio) is a bispecific monoclonal antibody (BCMA×CD3) immunotherapy. Mechanism: Simultaneously binds BCMA (TNFRSF17) on malignant plasma cells and CD3 on T cells to form an immune synapse, activate T cells, and drive T‑cell–mediated cytotoxicity and cytokine release against BCMA+ myeloma cells. Comparator: SOC regimens used in practice per G‑BA guidance post–triple-class failure, specific agents/mechanisms not specified. Targets/cells: BCMA on plasma/myeloma cells and CD3 on T cells, pathway focus is T‑cell redirection and cytotoxic killing of BCMA-expressing cells.